Improvement of cardiovascular remodelling by chymase inhibitor

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 4, 2016, Pages 387-393

  Takai, Shinji ^a   Jin, Denan ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Diabetes; Hyper cholesterolaemia; Hypertension; Matrix metalloproteinase 9; Transforming growth factor

Indexed keywords

CHYMASE INHIBITOR; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA; CHYMASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR TISSUE; DIABETES MELLITUS; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR FUNCTION; DRUG EFFECTS;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CHYMASES; HUMANS; SERINE PROTEINASE INHIBITORS;

EID: 84961215751     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12549     Document Type: Article

References (77)

1. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn. J. Pharmacol. 1993; 62: 207-10.
2. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin. Chim. Acta 1997; 265: 13-20.
3. Wintroub BU, Schechter NM, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic protainases. J. Invest. Dermatol. 1984; 83: 336-9.
4. Yamamoto D, Shiota N, Takai S, Ishida T, Okunishi H, Miyazaki M. Three-dimensional molecular modeling explains why catalytic function for angiotensin-I is different between human and rat chymases. Biochem. Biophys. Res. Commun. 1998; 242: 158-63.
5. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997; 412: 86-90.
6. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell α- and β-chymases. Biochim. Biophys. Acta 2000; 1480: 245-57.
7. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 1996; 58: 591-7.
8. Saito K, Muto T, Tomimori Y et al. Mouse mast cell protease-1 cleaves angiotensin I to form angiotensin II. Biochem. Biophys. Res. Commun. 2003; 302: 773-7.
9. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem. Biophys. Res. Commun. 2006; 350: 1026-31.
10. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: Effects of PA12 upon cardiac haemodynamics. Cardiovasc. Res. 2009; 82: 40-50.
11. Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides 2010; 31: 1540-55.
12. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS ONE 2011; 6: e28501.
13. Nagata S, Hatakeyama K, Asami M et al. Big angiotensin-25: A novel glycosylated angiotensin-related peptide isolated from human urine. Biochem. Biophys. Res. Commun. 2013; 441: 757-62.
14. De Young MB, Nemeth EF, Scarpa A. Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques. Arch. Biochem. Biophys. 1987; 254: 222-33.
15. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: The contributions of inorganic cations, pH, heparin and histamine. Biochim. Biophys. Acta 1995; 1267: 115-21.
16. Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J. Biol. Chem. 1989; 264: 21308-15.
17. Furubayashi K, Takai S, Jin D et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin. Chim. Acta 2008; 388: 214-16.
18. Takai S, Jin D, Sakaguchi M et al. A novel chymase inhibitor, BCEAB (4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)-3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid) suppressed cardiac fibrosis in cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 2003; 305: 17-23.
19. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J. Hypertens. 1998; 16: 657-64.
20. Touyz RM, He G, Wu XH, Park JB, Mabrouk ME, Schiffrin EL. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 2001; 38: 56-64.
21. Nakamura Y, Nakamura K, Matsukura T, Nakamura K. Vascular angiotensin converting activity in spontaneously hypertensive rats and its inhibition with cilazapril. J. Hypertens. 1988; 6: 105-10.
22. Okunishi H, Kawamoto T, Kurobe Y et al. Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin. Exp. Pharmacol. Physiol. 1991; 18: 649-59.
23. Kirimura K, Takai S, Jin D et al. Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens. Res. 2005; 28: 457-64.
24. Tom B, Garrelds IM, Scalbert E et al. ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: A matter of efficiency? Arterioscler. Thromb. Vasc. Biol. 2003; 23: 251-6.
25. Takai S, Jin D, Chen H et al. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J. Hypertens. 2014; 32: 1637-48.
26. Takai S, Sakonjo H, Fukuda K et al. A novel chymase inhibitor, 2-(5-formylamino- 6-oxo-2-phenyl-1, 6-dihydropyrimidine-1-yl)-N-[[3, 4-dioxo-1-phenyl-7-(2- pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J. Pharmacol. Exp. Ther. 2003; 304: 841-4.
27. Inoue N, Muramatsu M, Jin D et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 204: 359-64.
28. Humphrey JD. Mechanisms of arterial remodelling in hypertension: Coupled roles of wall shear an intramural stress. Hypertension 2008; 52: 195-200.
29. Ahmed SH, Clark L, Pennington WR et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-96.
30. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of MMP-1 and MMP-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am. J. Hypertens. 2004; 17: 770-4.
31. Fontana V, Silva PS, Belo VA et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: A relevant pharmacological target. Basic Clin. Pharmacol. Toxicol. 2011; 109: 130-7.
32. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2011; 301: H87-97.
33. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-78.
34. Uehara Y, Urata H, Sasaguri M et al. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 2000; 35: 55-60.
35. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc. Res. 2002; 55: 870-6.
36. -/- mice. Cardiovasc. Res. 2011; 89: 244-52.
37. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br. J. Pharmacol. 1999; 128: 523-9.
38. Fukuda D, Sata M. Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol. Ther. 2008; 118: 268-76.
39. Lee M, von Eckardstein A, Lindstedt L, Assmann G, Kovanen PT. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 1066-74.
40. Usami Y, Matsuda K, Sugano M et al. Detection of chymase-digested C-terminally truncated apolipoprotein A-I in normal human serum. J. Immunol. Methods 2011; 369: 51-8.
41. Fukuda M, Ohkubo T, Katsuya T et al. Association of a mast cell chymase gene variant with HDL cholesterol, but not with blood pressure in the Ohasama study. Hypertens. Res. 2002; 25: 179-84.
42. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-90.
43. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
44. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 2002; 20: 1879-86.
45. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-33.
46. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J. Endocrinol. 1999; 161: 317-22.
47. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-97.
48. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR. Pancreatic β-cells express phagocyte-like NAD(P)H oxidase. Diabetes 2003; 52: 1457-63.
49. 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int. J. Biochem. Cell Biol. 2004; 36: 330-9.
50. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J. Pharmacol. Sci. 2009; 110: 459-65.
51. Rafiq K, Sherajee SJ, Fan YY et al. Blood glucose level and survival in streptozotocin-treated human chymase transgenic mice. Chin. J. Physiol. 2011; 54: 30-5.
52. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J. Am. Soc. Nephrol. 2003; 14: 1738-47.
53. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 2006; 113: 1353-60.
54. Maeda Y, Inoguchi T, Takei R et al. Chymase inhibition prevents myocardial fibrosis through the attenuation of NOX4-associated oxidative stress in diabetic hamsters. J. Diabetes Investig. 2012; 3: 354-61.
55. Kaartinen M, van der Wal AC, van der Loos CM et al. Mast cell infiltration in acute coronary syndromes: Implications for plaque rupture. J. Am. Coll. Cardiol. 1998; 32: 606-12.
56. Pasterkamp G, Schoneveld AH, Hijnen DJ et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150: 245-53.
57. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn. J. Pharmacol. 2001; 86: 203-14.
58. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 2002; 71: 437-46.
59. Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J. Pharmacol. Exp. Ther. 2004; 309: 490-7.
60. Oyamada S, Bianchi C, Takai S et al. Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system. Basic Res. Cardiol. 2010; 105: 513-22.
61. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 2011; 339: 143-51.
62. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 1992; 327: 678-84.
63. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N. Engl. J. Med. 1988; 319: 80-6.
64. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337: 872-6.
65. Francis GS. Neuroendocrine activity in congestive heart failure. Am. J. Cardiol. 1990; 66: 33D-8D.
66. Schoemaker RG, Debets JJ, Struyker-Boudier HA, Smits JF. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J. Mol. Cell. Cardiol. 1991; 23: 187-97.
67. Jin D, Takai S, Yamada M et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc. Res. 2003; 60: 413-20.
68. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003; 107: 2555-8.
69. Li J, Jubair S, Janicki JS. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling. Hypertension 2015; 65: 328-34.
70. Zheng J, Chen Y, Pat B et al. Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog. Circulation 2009; 119: 2086-95.
71. Dell'italia LJ, Balcells E, Meng QC et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am. J. Physiol. 1997; 273: H961-70.
72. Pat B, Chen Y, Killingsworth C et al. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation 2010; 122: 1488-95.
73. Okumura K, Takai S, Muramatsu M et al. Human chymase degrades human fibronectin. Clin. Chim. Acta 2004; 347: 223-5.
74. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 238-43.
75. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
76. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 2012; 367: 2204-13.
77. Belkowski SM, Boot JD, Mascelli MA et al. Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease. Clin. Exp. Allergy 2009; 39: 1179-86.